anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neuroinflammation is an emerging clinical feature in spinal muscular atrophy (SMA). Characterizing neuroinflammatory cytokines in cerebrospinal fluid (CSF) in SMA and their response to nusinersen is important for identifying new biomarkers and understanding the pathophysiology of SMA. We measured twenty-seven neuroinflammatory markers in CSF from twenty SMA children at different time points, and correlated the findings with motor function improvement. At baseline, MCP-1, IL-7 and IL-8 were significantly increased in SMA1 patients compared to SMA2, and were significantly correlated with disease severity. After six months of nusinersen treatment, CSF levels of eotaxin and MIP-1β were markedly reduced, while IL-2, IL-4 and VEGF-A were increased. The decreases in eotaxin and MIP-1β were associated with changes in motor scores in SMA1. We also detected a transient increase in MCP-1, MDC, MIP-1α, IL-12/IL-23p40 and IL-8 after the first or second injection of nusinersen, followed by a steady return to baseline levels within six months. Our study provides a detailed profile of neuroinflammatory markers in SMA CSF. Our data confirms the potential of MCP-1, eotaxin and MIP-1β as new neuroinflammatory biomarkers in SMA1 and indicates the presence of a subtle inflammatory response to nusinersen during the early phase of treatment.
Hepatic adverse events have been reported in patients receiving a dolutegravir- or rilpivirine-containing regimen [see Adverse Reactions (6.1)]. Patients with underlying hepatitis B or C or marked elevations in transaminases prior to treatment may be at increased risk for worsening or development of transaminase elevations. Additionally, in some patients receiving dolutegravir-containing regimens, the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn. Cases of hepatic toxicity, including elevated serum liver biochemistries and hepatitis, have also been reported in patients receiving a dolutegravir- or rilpivirine-containing regimen who had no pre-existing hepatic disease or other identifiable risk factors. Drug-induced liver injury leading to acute liver failure has been reported with dolutegravir-containing products, including liver transplant with TRIUMEQ (abacavir, dolutegravir, and lamivudine). Monitoring for hepatotoxicity is recommended.
### Chlorzoxazone tablets USP 375 mg

One tablet three or four times daily. If adequate response is not obtained with this dose, the 375 mg tablets may be increased to two tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.

### Chlorzoxazone tablets USP 500 mg

One tablet three or four times daily. If adequate response is not obtained with this dose, it may be increased to one and one-half tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.

### Chlorzoxazone tablets USP 750 mg

1/3 tablet (250 mg) three or four times daily. Initial dosage for painful musculoskeletal conditions should be 2/3 tablet (500 mg) three or four times daily. If adequate response is not obtained with this dose, it may be increased to one tablet (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.
The invention relates to an application of a medicine derived from penicillium oxalicum seclenum ketonic acid H for resisting human oral epidermoid carcinoma. The compound has the effect of inhibiting proliferation of oral epidermoid carcinoma cells. The structural formula is as follows: . Culturing Penicillium oxalicum ( Penicillium oxalicum ) IBPT-6, obtaining a fermentation product, and separating and purifying the compound from the fermentation product. Experiments prove that the compound has better anti-tumor activity on human oral epidermoid cancer cells KB. Can be used for preparing human oral epidermoid carcinoma cell proliferation inhibiting medicine or antitumor medicine for human oral epidermoid carcinoma research.
Across six weekly 50-minute sessions and a booster session, advanced gastrointestinal cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that the team developed to guide mindfulness practices.
Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times. Participants carry about their normal activities during this period.
Usual care will be provided in the elderly centres. Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
<P>PROBLEM TO BE SOLVED: To provide an organic acid-containing granule from which oozing out of oily ingredients is controlled and a method for producing the same.  <P>SOLUTION: The organic acid-containing granule having a volume-average primary particle size of &le;50 &mu;m, includes 40-93 mass% of an organic acid, 0.1-30 mass% of oily ingredients, and 6-30 mass% of a water-soluble binder. The method for producing the same is described. Because of the fact that the volume-average primary particle size is not greater than 50 &mu;m, the organic acid-containing granule has a controlled oozing out of the oily ingredients in the granulation process and tabletting process, and an excellent shaping ability, even when the granule containing the oily ingredients is tabletted. The organic acid-containing granule is utilized as an intermediate for producing a bath agent.  <P>COPYRIGHT: (C)2011,JPO&amp;INPIT
Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
The invention discloses a rabbit viral hemorrhagic disease virus type 2 and application thereof in preparation of inactivated vaccines. The strain is preserved in China general microbiological culture collection center with the preservation name of rabbit viral hemorrhagic disease virus CD2020 strain and the preservation number of: CGMCC NO. 21092. The strain has great difference in comparison with the sequence of the virus of viral hemorrhagic disease of domestic rabbit, wherein the homology of main antigen amino acid is only 88.4%. The current rabbit viral hemorrhagic disease vaccine has no effective protective effect on the strain. Therefore, the invention provides the oil emulsion inactivated vaccine prepared from the rabbit viral hemorrhagic disease virus CD2020 strain, and the vaccine has a good immune effect, has small side effect after rabbit immunization, high safety and no adverse effect on the external environment.
Gender differences in rates of depression emerge during adolescence. Although rates of depression increase for both boys and girls during adolescence, the increase is more dramatic for girls. By late adolescence, girls are twice as likely as boys to develop depression. Because the transition to adolescence has been identified as a period of increased risk for girls, preventive interventions targeting early adolescent girls may promote resilience and prevent depression. The Girls in Transition (GT) program is a group intervention for 6th through 8th grade girls and is designed to address risk factors that are specific to girls. This study evaluates the effectiveness of the GT intervention in promoting coping strategies, preventing symptoms of depression and anxiety, and providing benefits in other outcomes related to depression, such as self-image.

Adolescents in this study will be assigned to one of two conditions: a group that will participate in the GT program in Spring 2006 (GT #1), or a waitlist control group that will participate in the GT program approximately two years later (GT #2). Students who participate in the program will attend eleven 90-minute after-school sessions led by the investigators. In the GT program, students learn cognitive-behavioral skills (such as strategies to cope with emotions and negative thinking) and problem-solving skills (such as assertiveness), and they discuss societal messages about women's appearance and roles. Adolescent participants will complete questionnaires about coping strategies, self-image, and feelings of hopelessness, depression and anxiety at five points during the study: at the beginning of the study (baseline) and at follow-ups approximately 6, 12, 16, and 24 months after baseline. In addition, students will complete an interview at baseline and then again 12 months later about experiences in which they have coped with stressful situations. Parents will complete a questionnaire about their child's life events at three assessment points (baseline and at follow-ups approximately 12 and 24 months after baseline).
PURPOSE:To improve the sequestering activity, pH buffer activity, soil protective emulsifying activity, thickening activity, etc. as a builder, by using a stevensitic magnesium sodium phyllosilicate exhibiting a particular X-ray diffraction pattern as a constituent material. CONSTITUTION:A stevensitic magnesium sodium phyllosilicate having a chemical compsn. represented by the formula MgxNaySi4O10(OH)2.Naz (wherein x>2 and y is 0-0.1, provided that x+y<3; and z is 0-1.0) and exhibiting an X-ray diffraction pattern at a spacing of 16-26Angstrom when being treated with ethylene glycol is used as a cleaner adjuvant. This synthetic stevensite is a white powder having a Hunter's whiteness index of at least 90% and does not color a cleaner when it is incorporated thereinto. Moreover, this adjuvant is swollen with water to form a colloid dispersed in water to thereby give a clear thickened liq., which has a viscosity of at least 50cps/25 deg.C at a concn. of 6wt.%.
Clear cell renal cell carcinoma (ccRCC) accounts for approximately 75-80% of all patients with renal cell carcinoma. Despite its prevalence, little is known regarding the key components involved in ccRCC metastasis. In this study, scRNA-seq analysis was employed to classify CD8+ T cells into four sub-clusters based on their genetic profiles and immunofluorescence experiments were used to validate two key clusters. Through gene set enrichment analysis, these newly identified sub-clusters were found to exhibit distinct biological characteristics. Notably, TYMP, TOP2A, CHI3L2, CDKN3, CENPM, and RZH2 were highly expressed in these sub-clusters, indicating a correlation with poor prognosis. Among these sub-clusters, CD8+ T cells (MT-ND4) were identified as potentially playing a critical role in mediating ccRCC metastasis. These results contribute to our understanding of CD8+ T cell heterogeneity in ccRCC and shed light on the mechanisms underlying the loss of immune response against cancer.
OBJECTIVE: Peritoneal mesometrial resection (PMMR) plus targeted compartmental lymphadenectomy (TCL) aims at removal of the locoregional cancer field in endometrial cancer (EC). Optimal locoregional control without adjuvant radiotherapy should be achieved concomitantly sparing systematic lymphadenectomy (LNE) for most of the patients. However, intermediate/high-risk EC is often definitely diagnosed postoperatively in simple hysterectomy specimen. Our aim was to evaluate feasibility and safety of a completing PMMR + TCL in patients following prior hysterectomy.
METHODS: We evaluated data from 32 patients with intermediate/high-risk EC treated with PMMR + TCL or systematic pelvic and periaortic LNE following prior hysterectomy. Perioperative data on disease characteristics and morbidity were collected and patients were contacted for follow-up to determine the recurrence and survival status.
RESULTS: We report data from 32 patients with a mean follow-up of 31.7 months. The recurrence rate was 12.5% (4/32) without any isolated locoregional recurrences. Only 21.9% of patients received adjuvant radiotherapy. Rates of intra- and postoperative complications were 6.3% and 18.8%, respectively.
CONCLUSION: Our data suggest that robotic PMMR can be performed following prior hysterectomy when previously unknown risk factors arise, albeit with a moderate increase in morbidity. Moreover, despite a relevant reduction of adjuvant radiotherapy, follow-up data suggest an excellent locoregional control even without adjuvant radiotherapy.
Venlafaxine Hydrochloride Extended-release Capsules, USP for once-a-day oral administration that contains venlafaxine hydrochloride a serotonin and norepinephrine reuptake inhibitor (SNRI). 

Venlafaxine is designated (R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[α-[(dimethylamino)methyl]-p-methoxybenzyl] cyclohexanol hydrochloride and has the empirical formula of C17H27NO2HCl. Its molecular weight is 313.86. The structural formula is shown as follows: 

Venlafaxine hydrochloride is a white to off-white crystalline solid, with a solubility of 572 mg/mL in water (adjusted to ionic strength of 0.2 M with sodium chloride). Its octanol:water (0.2 M sodium chloride) partition coefficient is 0.43. 

Drug release is controlled by diffusion through the coating membrane on the spheroids and is not pH-dependent. Capsules contain venlafaxine hydrochloride equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Inactive ingredients consist of ethylcellulose, hypromellose and sugar spheres. The empty hard gelatin capsule shells contain gelatin and titanium dioxide. The 37.5 mg capsules also contain iron oxide black. The 75 mg capsules also contain FD&C red No. 3 and FD&C yellow No. 6. The 150 mg capsules also contain iron oxide red and iron oxide yellow. 

The 37.5 mg, 75 mg and 150 mg capsules are imprinted with black and grey ink which contains iron oxide black, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac and strong ammonia solution. Grey ink also contains titanium dioxide.
BACKGROUND: Spheno-orbital meningioma (SOM) represents a unique variant of sphenoid wing meningiomas, distinguished by its propensity for bone infiltration and cranio-orbital involvement. SOM exhibits a considerable incidence of misdiagnosis and recurrence.
PURPOSES: To elucidate the clinical, radiological, and pathological characteristics of SOM.
METHODS: Review of electronic medical records, histopathology, radiological images and follow-up information of 100 SOM patients.
RESULTS: Of the 100 patients (28 males, 72 females) with SOM, mean age was 46.8 ± 12.6 years and prevalent symptoms were proptosis (99%). All the CT scans showed hyperostosis with 89.3% of the hyperostosis having an irregular edge. In MRI scans, dural tail sign was observed across all patients and the cranio-orbital tumors often penetrated temporal muscle (74.1%), extraocular muscle (74.1%) and lacrimal gland (63%). All the 100 patients underwent surgical intervention, and among them, 62 individuals received postoperative radiotherapy. Grade I resections had a lower recurrence rate(16.7%), which further decreased with the addition of radiotherapy(13.9%). In contrast, all patients with grade II or higher grade resections without radiotherapy experienced recurrence, indicating a higher risk associated with less complete tumor removal. The pathological examination revealed that intraorbital sections exhibited comparable tumor density to intraorbital SOM tumors, along with increased fibrous density but decreased vascular distribution.
CONCLUSIONS: Radiological characteristics of SOM included cranio-orbital tumors, hyperostosis of the sphenoid wing with an irregular edge, and dural tail sign. Combination of gross total resection and adjuvant radiotherapy was recommended to minimize recurrence rate. Intracranial SOM tumors tended to be softer and more bleed-prone than intraorbital sections, necessitating surgical precision.
It was planned to determine the effect of laughter yoga on the secondary traumatic stress and depression levels experienced by midwifery students due to the use of social media after the earthquake. The study will be implemented according to the CONSORT 2010 guidelines.

The research will be carried out in Health Sciences University, Hamidiye Faculty of Health Sciences, Midwifery department classroom. In pre-research classrooms; An environment with good lighting, sound systems and allowing individuals to move comfortably will be arranged. Hamidiye Faculty of Health Sciences Midwifery Department 3rd year students who volunteered to participate in the study will be determined as the intervention (n:42) and control (n:42) groups with the numbers assigned by the researchers via the https://www.randomizer.org/ site. An introductory information form will be applied to all students. A total of 8 sessions of laughter yoga, 2 sessions per week, will be applied to midwifery students in the intervention group of the research. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Each session will consist of groups of 7 people. Before starting the laughter yoga session, an information meeting will be held with midwifery students who volunteered to participate in the study and were assigned to the intervention group. Midwifery students will be administered "Secondary Traumatic Stress Scale for Social Media Users" and "Beck Depression Inventory" before and 4-6 weeks after the application. No intervention will be applied to the control group midwives, and "Secondary Traumatic Stress Scale for Social Media Users" and "Beck Depression Inventory" will be administered again when they are included in the study and 4-6 weeks later.
PURPOSE:To provide a propolis composition excellent in dispersibility in water, and another of propolis composition good in stability and yield. CONSTITUTION:A propolis composition contains a propolis extract and saponin. The saponin is e.g. quillaia saponin, soybean saponin or carrot saponin. This composition may be incorporated with sugar, sugar alcohol or a branched cyclodextrin. This propolis composition can be obtained by an extracting solvent and saponin to a propolis technical product followed by extracting the active ingredient(s) in the technical product. Another propolis composition free from ethanol or with low content thereof can be obtained by incorporating a composition comprising a propolis extract and ethanol with saponin or saponin plus sugar or sugar alcohol or a branched cyclodextrin followed by concentration.
When stopping chest compressions to check manual palpation every 2 minutes, an ultrasound scan of the carotid artery is performed. Whether or not return of spontaneous circulation is determined based on the compressibility and pulsatility of the carotid artery, and the time taken from the start of the ultrasound scan to the determination is recorded.
An intelligent notification system provides an intelligent notification to a client device associated with a user so as to improve the quality of service to a user. Rather than send a user monotonous or routine reminders that do not reflect current or timely information, the intelligent notification is based on user data associated with the user. By aggregating user data associated with a schedule of the user, the intelligent notification system can generate an intelligent notification that provides information to the user that is useful and pertinent. For example, a user may have already completed a regularly schedule and as such no reminder is necessary. The intelligent notification can, in lieu of a reminder, send the user an encouraging or informative intelligent reminder. In this way, a user is not inundated with stale reminders but rather receives accurate, relevant and informative intelligent notifications.
Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
A system for detecting one or more physical assessment parameters of a subject includes a sensing patch and a processor. The sensing patch is configured to sense signals from the subject corresponding to one or more physical assessment parameters, reduce sensed parameter data corresponding to the sensed signals, and transmit the sensed parameter data. The sensing patch also includes at least one adjustable sensing patch parameter. The processor is separate from the sensing patch and configured to receive the sensed parameter data from the sensing patch and transmit a command to the sensing patch. The sensing patch is configured to perform different amounts of data reduction on the sensed parameter data before transmitting the sensed parameter data to the processor. These different amounts of data reduction are determined at least in part by one or more system parameters.
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. Patients may have received up to 2 prior chemotherapy regimens for small cell lung carcinoma, but no prior therapy with an m-TOR inhibitor. RAD001 will be administered orally at a dose of 10 mg daily. A cycle will be defined as 3 weeks of study drug administration, and patients will have tumor measurements every 2 cycles. Study participation will continue until disease progression or intolerable toxicities. In addition, in patients who consent, archival tumor tissue (paraffin block from original biopsy) will be collected for research purposes.
BACKGROUND: Existing patient-reported outcome measures (PROMs) for chronic rhinosinusitis (CRS) use a variety of recall periods and response scales to assess CRS symptom burden. Global perspectives of CRS patients regarding optimal recall periods and response scales for CRS PROMs are unknown.
METHODS: This was a multi-center, cross-sectional study recruiting 461 CRS patients from sites across the United States, Saudi Arabia, New Zealand, and Austria. Participants chose which CRS symptom recall period (1 day, 2 weeks, 1 month, >1 month) was most reflective of their current disease state and upon which to best base treatment recommendations (including surgery). Participants also chose which of six response scales (one visual analogue scale and five Likert scales ranging from four to eight items) was easiest to use, understand, and preferred.
RESULTS: A plurality of participants (40.0%) felt their CRS symptoms' current state was best reflected by a 1-month recall period. However, most patients (56.9%) preferred treatment recommendations to be determined by symptoms experienced over a >1 month period. The four- and five-item Likert scales were the easiest to understand (26.0% and 25.4%, respectively) and use (23.4% and 26.7%, respectively). The five-item (26.4% rating it most preferred and 70.9% rating it preferred) and four-item Likert (22.3% rating it most preferred and 56.4% rating it preferred) response scales were most preferred.
CONCLUSION: Future PROMs for CRS should consider assessment of symptoms over a 1-month period and use a four- or five-item Likert response scale to reflect global patient preferences. These findings also inform interpretation of current CRS PROMs.